PAK6
MOLECULAR TARGETp21 (RAC1) activated kinase 6
PAK6 (p21 (RAC1) activated kinase 6) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting PAK6
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | tozasertib | 4.33 | 75 |
| 2 | ruxolitinib | 4.23 | 68 |
| 3 | neratinib | 3.66 | 38 |
| 4 | tae 684 | 3.43 | 30 |
| 5 | fedratinib | 3.40 | 29 |
| 6 | jnj 7706621 | 3.09 | 21 |
| 7 | at 9283 | 3.09 | 21 |
| 8 | lestaurtinib | 3.04 | 20 |
| 9 | pf 03758309 | 3.00 | 19 |
| 10 | r 406 | 2.83 | 16 |
| 11 | kw 2449 | 2.64 | 13 |
| 12 | gsk 690693 | 2.64 | 13 |
| 13 | bms 754807 | 2.30 | 9 |
| 14 | ucn 01 | 1.79 | 5 |
| 15 | kenpaullone | 1.10 | 2 |
About PAK6 as a Drug Target
PAK6 (p21 (RAC1) activated kinase 6) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented PAK6 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
PAK6 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.